NCT02590627View on ClinicalTrials.gov

In-vivo Efficacy and Safety of Artemether/Lumefantrine Vs Dihydroartemisinin-piperaquine for Treatment of Uncomplicated Malaria and Assessment of Parasite Genetic Factors Associated With Parasite Clearance or Treatment Failure

PHASE4CompletedINTERVENTIONAL

Enrollment

509

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

Malaria

Interventions

DRUG

Artemether-lumefantrine

DRUG

Dihydroartemisinin-piperaquine

Trial Locations (2)

255

Ujiji Health Centre, Ujiji

Muheza Disignated District Hospital, Muheza

All Listed Sponsors

collaborator

Ministry of Health and Social Welfare, Tanzania

OTHER_GOV

collaborator

World Health Organization

OTHER

lead

National Institute for Medical Research, Tanzania

OTHER_GOV

NCT02590627 - In-vivo Efficacy and Safety of Artemether/Lumefantrine Vs Dihydroartemisinin-piperaquine for Treatment of Uncomplicated Malaria and Assessment of Parasite Genetic Factors Associated With Parasite Clearance or Treatment Failure | Biotech Hunter | Biotech Hunter